Monopar Therapeutics (NASDAQ:MNPR) Trading Up 0.4% - Here's What Happened

Monopar Therapeutics Inc. (NASDAQ:MNPR - Get Free Report)'s stock price traded up 0.4% during trading on Wednesday . The stock traded as high as $36.55 and last traded at $34.65. 11,648 shares changed hands during mid-day trading, a decline of 97% from the average session volume of 358,561 shares. The stock had previously closed at $34.51.

Analysts Set New Price Targets

MNPR has been the subject of a number of research analyst reports. Jones Trading reiterated a "hold" rating on shares of Monopar Therapeutics in a research report on Wednesday, April 2nd. Wall Street Zen upgraded shares of Monopar Therapeutics from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. Piper Sandler reiterated an "overweight" rating and issued a $76.00 target price on shares of Monopar Therapeutics in a report on Wednesday, March 19th. Finally, HC Wainwright reiterated a "buy" rating and issued a $40.00 target price on shares of Monopar Therapeutics in a report on Tuesday, April 1st. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, Monopar Therapeutics has an average rating of "Moderate Buy" and an average target price of $55.33.

Monopar Therapeutics Trading Down 0.9%

The firm's fifty day moving average price is $37.17 and its 200-day moving average price is $34.08. The company has a market cap of $204.97 million, a P/E ratio of -17.02 and a beta of 0.99.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last issued its earnings results on Tuesday, May 13th. The company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.65) by $0.27. As a group, research analysts forecast that Monopar Therapeutics Inc. will post -1.65 earnings per share for the current fiscal year.

Insider Buying and Selling at Monopar Therapeutics

In other news, major shareholder Tactic Pharma Llc sold 33,334 shares of the company's stock in a transaction that occurred on Wednesday, April 2nd. The shares were sold at an average price of $35.00, for a total transaction of $1,166,690.00. Following the transaction, the insider now directly owns 822,255 shares in the company, valued at approximately $28,778,925. This represents a 3.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 20.50% of the company's stock.

Hedge Funds Weigh In On Monopar Therapeutics

Large investors have recently modified their holdings of the stock. JPMorgan Chase & Co. acquired a new position in shares of Monopar Therapeutics during the fourth quarter worth approximately $45,000. RA Capital Management L.P. acquired a new position in shares of Monopar Therapeutics during the fourth quarter worth approximately $11,247,000. Geode Capital Management LLC raised its stake in shares of Monopar Therapeutics by 174.4% during the fourth quarter. Geode Capital Management LLC now owns 38,596 shares of the company's stock worth $849,000 after buying an additional 24,530 shares during the last quarter. Janus Henderson Group PLC bought a new stake in shares of Monopar Therapeutics during the fourth quarter worth approximately $23,435,000. Finally, ADAR1 Capital Management LLC bought a new stake in shares of Monopar Therapeutics during the fourth quarter worth approximately $2,861,000. 1.83% of the stock is currently owned by institutional investors and hedge funds.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.